Form 4: Altimmune Executive Reports Stock Transaction
Insider Transaction (Form 4)
Christophe Arbet-Engels, Chief Medical Officer of Altimmune, Inc., reported multiple transactions in common stock on October 1, 2026.
Summary
- Option exercise/conversion: acquired 37,500 Common Stock, par value $0.0001 on October 1, 2026; holds 37,500 after (Direct).
- Tax/exercise-price withholding: disposed of 12,679 Common Stock, par value $0.0001 at $2.76 ($34,994) on October 1, 2026; holds 24,821 after (Direct).
- Option exercise/conversion: disposed of 37,500 Restricted Stock Units on October 1, 2026; holds 112,500 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Christophe Arbet-Engels — Officer (Chief Medical Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock, par value $0.0001 | 37,500 | — | — | 37,500 |
| 2026-10-01 | Tax/exercise-price withholding | Common Stock, par value $0.0001 | 12,679 | $3 | $35.0K | 24,821 |
| 2026-10-01 | Option exercise/conversion | Restricted Stock Units | 37,500 | — | — | 112,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (37,500 shares) |
| 2026-10-01 | Tax/exercise-price withholding (12,679 shares) |
| 2026-10-01 | Option exercise/conversion (37,500 shares) |
Keywords
insider transaction, Form 4, ALT, Altimmune, Inc., neutral, Christophe Arbet-Engels
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.